Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Completed · Phase 1/Phase 2

Conditions studied: Myelofibrosis, Polycythemia Vera, Thrombocytosis

In brief

To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia Myelofibrosis (PET-MF).

Key facts

Study ID

NCT00509899

Run by

Incyte Corporation

People needed

154

Starts

2007-06-01

Expected to finish

2017-02-01

Last updated by the study team

2018-03-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosed with PMF or Post-PV/ET MF
• Patients with myelofibrosis requiring therapy
• Adequate bone marrow reserve

You may not qualify if…

• Received anti-cancer medications or investigational therapy in the past 14 days

Where it is running

• Study site — Rochester, Minnesota, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.